- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye
- Interventions
- Vehicle, SDP-4 Ophthalmic Solution (1.0%)
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Newport Beach, California • Pittsburg, Kansas + 6 more
- Conditions
- Myopia, Progressive
- Interventions
- OT-101 Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Ocumension (Hong Kong) Limited
- Other
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Active Comparator EBI-005, Placebo Comparator
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 45
- States / cities
- Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Northbrook, Illinois • Garner, North Carolina • Shelby, North Carolina + 2 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 25
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 20 more
- Conditions
- Ocular Redness
- Interventions
- Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Glendale, California • Garner, North Carolina • Cranberry Township, Pennsylvania + 2 more
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Interventions
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution
- Drug · Other
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Roswell, Georgia
- Conditions
- Dry Eye
- Interventions
- EBI-005, Placebo
- Drug
- Lead sponsor
- Eleven Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
- Conditions
- Neurotrophic Keratitis
- Interventions
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Biological
- Lead sponsor
- Claris Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 45
- States / cities
- Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more
- Conditions
- Ocular Redness, Eye Irritation
- Interventions
- Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 5 more
- Conditions
- Dry Eye
- Interventions
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 26
- States / cities
- Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Interventions
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas